You are here

Article Text

Article menu

This article has a Reply. Please see:

Download PDFPDF
Correspondence
Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak
  1. Jan Holubar1,
  2. Moglie Le Quintrec2,
  3. Hind Letaief1,
  4. Jean Luc Faillie3,
  5. Yves-Marie Pers1,
  6. Christian Jorgensen1
  1. 1 Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHRU Lapeyronie, Montpellier, France
  2. 2 Nephrology Unit, CHRU Lapeyronie, Montpellier, France
  3. 3 Medical Pharmacology and Toxicology Unit, CHRU Lapeyronie, Montpellier, France
  1. Correspondence to Dr Jan Holubar, Herault, University of Montpellier Faculty of Medicine, Montpellier 34295, France; j.holubar11{at}gmail.com

http://dx.doi.org/10.1136/annrheumdis-2020-217919

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The emergence and spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the resulting COVID-19 disease, have had a tremendous impact on public health and the world economy. Thus far, COVID-19 does not appear to be more severe in immunocompromised patients, but relevant data are scarce.1 Conversely to what was initially thought, patients with systemic lupus erythematosus (SLE) are also involved.2 3 In an article by Mathian et al,4 some severe forms of COVID-19 infection were described in 17 patients with SLE, particularly in those with renal failure or obesity. This greater susceptibility might arise from dysregulation of ACE2 and interferon expression.5 At the same time, hydroxychloroquine (HCQ), the reference standard-of-care treatment for SLE, has emerged as a potential treatment option for COVID-19. HCQ has shown the potential to inhibit the viral replication in vitro, and several clinical trials are under way to evaluate its clinical efficacy.6 Building on the report of Mathian et al,4 we would like to share our experience from another French university centre to further the discussion of SLE patient outcomes during the COVID-19 outbreak. Here we aim to address COVID-19 disease progression …

    View Full Text

    Footnotes

    • Contributors JH conceived the design of the study, collected and analysed the data, and wrote the first draft of the manuscript. MLQ, JLF, YMP participated in its design and helped draft the manuscript. HL participated in the data collection. CJ supervised the design of the study, analysed the data and helped draft the manuscript. All authors read and approved the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Ethics approval The study was approved by the institutional review board (IRB-MTP_2020_04_202000446).

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles